+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09931(GTF3C2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09931(GTF3C2 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The GTF3C2 antibody targets the General Transcription Factor 3C Polypeptide 2 (GTF3C2), a subunit of the TFIIIC complex, which is essential for RNA polymerase III (Pol III)-mediated transcription. The TFIIIC complex binds to promoter regions of small non-coding RNAs, such as tRNAs, 5S rRNA, and other regulatory RNAs, facilitating the assembly of the transcription preinitiation complex. GTF3C2 plays a structural role in stabilizing the TFIIIC complex and anchoring it to specific DNA elements. It contains tetratricopeptide repeat (TPR) domains, which mediate protein-protein interactions critical for complex integrity and recruitment of cofactors.

Research using GTF3C2 antibodies has highlighted its involvement in cellular processes like ribosome biogenesis, cell growth, and proliferation. Dysregulation of GTF3C2 or Pol III transcription is linked to cancers, neurological disorders, and viral infections, where abnormal RNA synthesis contributes to pathogenesis. Antibodies against GTF3C2 are widely used in techniques such as Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to study its expression, localization, and DNA-binding activity. These studies help elucidate mechanisms of transcriptional regulation and potential therapeutic targets. Recent investigations also explore its role in cellular stress responses and interactions with oncogenic signaling pathways, underscoring its broader biological relevance.